Ndx Pharma Labs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 9 Months
- Last Filing with ROC 31 Mar 2020
- Revenue Growth %
- Profit Growth -5.03%
- Ebitda -12.13%
- Net Worth -21.62%
- Total Assets -7.70%
About Ndx Pharma Labs
Ndx Pharma Labs Private Limited (NPLPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 April 2018 (Six years and nine months 12 days old ). Its registered office is in Guntur, Andhra Pradesh, India.
The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Venkata Mynampati and Venkatanaga Mynampati serve as directors at the Company.
Company Details
- Location
Guntur, Andhra Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24304AP2018PTC108231
- Company No.
108231
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Apr 2018
- Date of AGM
16 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Who are the key members and board of directors at Ndx Pharma Labs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkata Mynampati  | Managing Director | 20-Apr-2018 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Venkatanaga Mynampati | Director | 20-Apr-2018 | Current |
Financial Performance of Ndx Pharma Labs.
Ndx Pharma Labs Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 5.03% decrease in profit. The company's net worth observed a substantial decline by a decrease of 21.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ndx Pharma Labs?
Unlock access to Ndx Pharma Labs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Slim Infra Private LimitedVenkata Mynampati and Venkatanaga Mynampati are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ndx Pharma Labs?
Unlock and access historical data on people associated with Ndx Pharma Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ndx Pharma Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ndx Pharma Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.